To include your compound in the COVID-19 Resource Center, submit it here.

Clovis sinks as rociletinib questions linger

Clovis Oncology Inc. (NASDAQ:CLVS) lost $3.40 (18%) to $15.77 on Friday after FDA reviewers asked an advisory committee whether the company will need to submit more data before the agency decides whether to approve lung cancer candidate rociletinib ( CO-1686). The panel is also

Read the full 444 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE